Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISLAND2: Vismodegib + Pirfenidone in IPF
NCT02648048Phase 1Completed
- Sponsor
- Roche
- Start
- Jan 2016
- Primary completion
- Nov 2016
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of vismodegib in idiopathic pulmonary fibrosis (IPF), sponsored by Roche. Primary endpoints: Percentage of Participants with Serious and Non-Serious Adverse Events at 28 weeks, Percentage of Participants with Discontinuation of Any Study Medication Due to a Drug-Related Adverse Event at 28 weeks and 2 more. Started Jan 2016; status: completed.
02
Drugs
vismodegib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02648048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02648048.